A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer’s Disease in Taiwan

Overview of attention for article published in Advances in Therapy, April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 1 news outlet

twitter: 1 X user

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 26 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer's Disease in Taiwan.

Alzforum, 12 Apr 2019

Chang CC, Peng GS, Lai TJ, Li CH, Liu CK. A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.